Dr. Kadmon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6620 Main St
Ste 1325
Houston, TX 77030
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Urology, 1978 - 1980- Washington University/B-JH/SLCH ConsortiumResidency, Surgery, 1977 - 1978
- Washington University/B-JH/SLCH ConsortiumInternship, Transitional Year, 1976 - 1977
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1972
Certifications & Licensure
TX State Medical License 1986 - 2026
MO State Medical License 1980 - 2025- American Board of Urology Urology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer Start of enrollment: 2006 Aug 01
Publications & Presentations
PubMed
- 41 citationsThe Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled TrialAlvin M. Matsumoto, Lisa Tenover, Michael McClung, David F. Mobley, Jack Geller
The Journal of Urology. 2002-05-01 - 135 citationsTreatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-contro...Gerald L. Andriole, H. A. Guess, Jonathan I. Epstein, H. Wise, D. Kadmon
Urology. 1999-01-01 - 33 citationsCopenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine.Warren D. W. Heston, Dov Kadmon, David W. Lazan, William R. Fair
The Prostate. 1982-01-01
Other
- Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasiaKadmon D, Cunningham GR
http://www.uptodate.com/contents/clinical-manifestations-and-diagnostic-evaluation-of-benign-prostat
UpToDate, Wolters Kluwer Health - 2013-03-18 - Epidemiology and pathogenesis of benign prostatic hyperplasiaKadmon D, Cunningham GR
http://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-benign-prostatic-hyperplasia
UpToDate, Wolters Kluwer Health - 2012-02-11 - Medical treatment of benign prostatic hyperplasiaKadmon D, Cunningham GR
http://www.uptodate.com/contents/medical-treatment-of-benign-prostatic-hyperplasia
UpToDate, Wolters Kluwer Health - 2012-10-31 - Join now to see all
Grant Support
- Clinical Trial: A Phase I Study Of In-Situ, Neoadjuvant, Pre-Radical ProstatectoNational Center For Research Resources2008–2010
- A Phase I Study Of In-Situ, Neoadjuvant, Pre-Radical Prostatectomy RTVP-1 GENNational Center For Research Resources2007
- Development Of RTVP-1 Gene Therapy For Prostate CancerNational Cancer Institute2002
- Career Development ProgramNational Cancer Institute2002
- Neoadjuvant PRE Radical Prostatectomy Gene TherapyNational Center For Research Resources1999–2001
- Biological Therapy For Prostate CancerNational Cancer Institute1996–2001
- Pharmacological Intervention In Prostate CancerNational Cancer Institute1992–1995
- Polyamine Based SCAN For Metastatic Prostate CancerNational Cancer Institute1986–1988
- Polyamine Based SCAN For Metastatic Prostate CancerNational Cancer Institute1985–1986
- Polyamine Based SCAN For Metastatic Prostate CancerNational Cancer Institute1985
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
